ASX:MEBMedibio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medibio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add 0.0070 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.01Now: A$0.01▼A$0.0150-Day RangeA$0.01MA: A$0.01▼A$0.0152-Week RangeA$0.01Now: A$0.01▼A$0.03Volume1.26 million shsAverage VolumeN/AMarket Capitalization$6.97 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Medibio Limited, a health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States. It is involved in the research, development, and commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. Medibio Limited has a research agreement with the Department of Biomedical Sciences of Humanitas University for the development of mental health software products. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was founded in 1998 and is headquartered in Savage, Minnesota.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Medibio. Previous Next 2.0 Community Rank Outperform VotesMedibio has received 4 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedibio has received 6 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedibio has received 60.00% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medibio and other stocks. Vote “Outperform” if you believe MEB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedibio does not currently pay a dividend.Dividend GrowthMedibio does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medibio insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Medibio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medibio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedibio has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.53 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:MEB Previous Symbol CUSIPN/A CIKN/A Webwww.medibio.com.au Phone952-222-0551Debt Debt-to-Equity Ratio1.02 Current Ratio1.53 Quick Ratio1.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.47 million Price / Sales4.73 Cash FlowA$0.00 per share Price / Cash Flow3.50 Book ValueA$0.01 per share Price / Book0.54Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares995,129,984Market Cap$6.97 million Next Earnings DateN/A OptionableNot Optionable Receive MEB News and Ratings via Email Sign-up to receive the latest news and ratings for MEB and its competitors with MarketBeat's FREE daily newsletter. Medibio (ASX:MEB) Frequently Asked Questions How has Medibio's stock been impacted by COVID-19 (Coronavirus)? Medibio's stock was trading at A$0.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MEB stock has increased by 0.0% and is now trading at A$0.01. View which stocks have been most impacted by Coronavirus. Has Medibio been receiving favorable news coverage? News coverage about MEB stock has trended negative this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medibio earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutMedibio. Who are some of Medibio's key competitors? Some companies that are related to Medibio include Prana Biotechnology (PBT), Armata Pharmaceuticals (ARMP), Galena Biopharma (SLS), Bio-Gene Technology (BGT), Mereo BioPharma Group (MPH), Fusion Antibodies (FAB), NovaBay Pharmaceuticals (NBY), Oragenics (OGEN), Bionomics (BNO), Acrux (ACR), Rezolute (RZLT), Skinbiotherapeutics (SBTX), Quest PharmaTech (QPT), Can-Fite Biopharma (CANF) and Ceapro (CZO). View all competitors. Who are Medibio's key executives? Medibio's management team includes the following people: Mr. David B. Kaysen, Chairman, CEO & MD (Age 69)Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Joint Company Sec. & Director (Age 46)Ms. Peggy Morgan, Corp. ControllerMs. Stephanie Ottens, Investor Relations DirectorMr. Josh Purdy, PR Director What is Medibio's stock symbol? Medibio trades on the ASX under the ticker symbol "MEB." What is Medibio's stock price today? One share of MEB stock can currently be purchased for approximately A$0.01. How big of a company is Medibio? Medibio has a market capitalization of $6.97 million and generates $1.47 million in revenue each year. What is Medibio's official website? The official website for Medibio is www.medibio.com.au. How can I contact Medibio? The company can be reached via phone at 952-222-0551. This page was last updated on 5/27/2020 by MarketBeat.com Staff
